Form 4: Patrick Zenner Reports Acquisition of Cartesian Therapeutics Stock and Options

Director Patrick Zenner reports acquiring common stock and stock options in Cartesian Therapeutics, Inc.

Summary

• Patrick Zenner, a director of Cartesian Therapeutics, Inc., filed a Form 4 detailing changes in beneficial ownership.
• On January 2, 2025, Zenner acquired 2,600 shares of common stock and 7,800 stock options.
• The common stock was acquired at $0 per share.
• The stock options have an exercise price of $16.93 and expire on January 1, 2035.
• Zenner also holds 7,600 stock options with an exercise price of $19.656, vesting monthly until January 2, 2027, and expiring on January 1, 2034.
• Following these transactions, Zenner directly owns 10,374 shares of common stock and 15,400 stock options.
• The reported securities amounts have been adjusted to reflect a 1-for-30 reverse stock split that occurred on April 4, 2024.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. A director acquiring shares and options suggests confidence, but it's a routine filing.

Positives

• A director's acquisition of company stock and options can be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. These filings are closely watched by investors for signals about management's confidence in the company's prospects.

Stakeholder Impact

• The acquisition of shares and options by a director could positively influence shareholder sentiment.

Key Dates